hVIVO (LON:HVO) Trading 12.9% Higher - Here's Why

Key Points

• hVIVO's stock price surged by 12.9% during mid-day trading, reaching GBX 7.79 ($0.10) after closing at GBX 6.90 ($0.09).
• Analysts forecast a positive growth outlook, with Peel Hunt setting a price target of GBX 21 and other analysts offering a consensus target of GBX 23.
• The company's recent earnings report showed a net margin of 25.96% and a return on equity of 47.93%, indicating strong financial performance.

hVIVO plc (LON:HVO - Get Free Report)'s stock price traded up 12.9% during mid-day trading on Monday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.79 ($0.10). 8,529,418 shares changed hands during mid-day trading, an increase of 188% from the average session volume of 2,964,574 shares. The stock had previously closed at GBX 6.90 ($0.09).

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Peel Hunt reiterated an "add" rating and issued a GBX 21 price objective on shares of hVIVO in a research report on Tuesday, July 29th. Shore Capital reduced their target price on shares of hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of GBX 23.

hVIVO Stock Up 13.0%

The firm's 50-day simple moving average is GBX 9.27 and its 200 day simple moving average is GBX 12. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market capitalization of £53.60 million, a P/E ratio of 1,012.99 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last released its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. As a group, research analysts expect that hVIVO plc will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.